Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
about
DPP4 in DiabetesCardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonistsGemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes MellitusTissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors.Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female miceSelective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesGhrelin: a new incretin enhancer therapy?Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic ControlDipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice.Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario.The contributions of dipeptidyl peptidase IV to inflammation in heart failure.Effects of Incretin-Based Therapies on Diabetic Microvascular Complications.Elevated circulating fasting glucagon-like peptide-1 in surgical patients with aortic valve disease and diabetes.Letter: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9).Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus.Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Ameliorates Angiotensin II-Induced Cardiac Diastolic Dysfunction in Male Mice.Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial.Cellular Mechanisms Underlying Obesity-Induced Arterial Stiffness.Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor.Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.Possible vasculoprotective role of linagliptin against sodium arsenite-induced vascular endothelial dysfunction.Hemorheologic Alterations in Patients with Type 2 Diabetes Mellitus Presented with an Acute Myocardial Infarction.
P2860
Q26797335-C8526AF1-58B3-4178-965E-294627D98B04Q26823085-0DD95480-8CA7-4623-BDA9-D9EC751DCA01Q28066209-F1983CDE-AFD2-4CBC-A959-6570963F4D4CQ31036099-C7F76FD4-CD6B-40CB-B2C1-ACA62ED8D8D0Q33644666-559751FE-EE6D-4D35-9B2F-81573210B935Q34994502-B64F37C6-71C5-4778-8FB8-CF441B3B7AC9Q35532285-DF72105A-0E36-438F-B8BE-5BA031FDD9FAQ36930813-436DEF84-4FCE-4A01-BA4D-7B1AC559F4FDQ37080167-77019A50-AC1D-40C8-9037-0BC3684D561FQ37677889-BC968567-4B15-4057-8E8E-5FEF6829508CQ38315999-4277333E-631A-49FC-B1A3-CF89C9094B30Q38648862-A48CA55F-1E94-4122-A740-682468035BCFQ39751432-245C6875-5B48-45FD-8ECA-8BB405697A11Q42366423-52BAA671-C880-49B7-8B87-A66B614D6569Q42374475-8C12B905-99A6-4AB2-94D8-C3EE9173B570Q42872673-21A1AA06-286B-4015-BDFE-E5D1CE61AB52Q47137374-481B4AD0-9CA9-45E8-90A9-9875DF3BE5B1Q47699621-AA99ECD4-4C53-4E76-BDEA-7C39B1241FB1Q48108721-04A1D117-4DED-4D80-9235-C3C3037325D5Q49592715-A068BE33-393D-4701-ACC6-808ADE34E20AQ49789137-82C4D634-FEDD-4A37-BE47-F47B0E2E0B8DQ50101761-EF9D8456-130B-4CF5-AC1E-57D635067928Q52594764-CA0F332E-7A87-4C22-8D9D-1E811D3E6180Q52718518-44D6B402-9164-4C2B-B599-864A90CDD3EBQ53301648-2C4D69C5-5740-4346-BE74-AD5C64F4E299Q55026843-A7A26C2D-98BC-4FBD-8979-91190E77D4DD
P2860
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
@ast
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
@en
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
@nl
type
label
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
@ast
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
@en
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
@nl
prefLabel
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
@ast
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
@en
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
@nl
P2093
P2860
P1476
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
@en
P2093
Annayya R Aroor
Guanghong Jia
James R Sowers
Vincent G DeMarco
P2860
P304
P356
10.1152/AJPHEART.00209.2014
P577
2014-08-01T00:00:00Z